Arca
Skip to content
Tools
Tools

Granulomatosis with polyangiitis

Drug research and approvals for granulomatosis with polyangiitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 24 studies of granulomatosis with polyangiitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 4 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 24
  • Trials authorized in Canada: 4
  • FDA orphan approvals: 4
  • EU medicines: 0

Recruiting now

Newest posted first, of 24 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

  • RituximabB-lymphocyte antigen CD20 binding agent
  • AvacopanC5a anaphylatoxin chemotactic receptor antagonist

Phase 3 9

Phase 2 6

Phase 1 or earlier 3

How its trials ended

103 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 22 whose ending is known, 41% met their primary endpoint, 14% missed it and 45% stopped early.

  • Completed, result not reported4241%
  • Ongoing2524%
  • Status unknown1414%
  • Met its primary endpoint99%
  • Stopped: other or unclear44%
  • Missed its primary endpoint33%
  • Stopped: enrollment or feasibility33%
  • Stopped: funding22%
  • Stopped: sponsor or business decision11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Mar 27, 2025A phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with…YTB323 (rapcabtagene autoleucel)Novartis PharmaceuticalsPending
Feb 13, 2025Safe effective therapy with low-dose glucocorticoid in anca-associated vasculitis (safe-low) trialCyclophosphamide / PrednisoneOttawa Hospital Research InstituteOngoing
Apr 24, 2024A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active anca-associated vasculitisIptacopan (LNP023)Novartis PharmaceuticalsClosed
Sep 13, 2023A phase 2, double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of NS-229 in the treatment of eosinophilic granulomatosis…NS-229NS Pharma IncOngoing

FDA orphan designations

Approved first, then open designations, newest first
Sep 17, 2024FasenraTreatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)AstraZeneca Pharmaceuticals LPApproved
Oct 7, 2021TavneosAs an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis…ChemoCentryx, Inc.Approved
Sep 27, 2019RituxanRITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with…Genentech, Inc.Approved
Jun 6, 2019NucalaNUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis…GlaxoSmithKline LLCApproved
Apr 14, 2025Small molecule, selective Janus kinase (JAK) 1 inhibitorTreatment of eosinophilic granulomatosis with polyangiitisNS Pharma, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.